<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424047</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-010</org_study_id>
    <nct_id>NCT00424047</nct_id>
  </id_info>
  <brief_title>A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma</brief_title>
  <official_title>The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose
      dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for
      subjects with relapsed or refractory multiple myeloma.&quot;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2003</start_date>
  <completion_date type="Actual">November 12, 2013</completion_date>
  <primary_completion_date type="Actual">November 1, 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of Time to Tumor Progression (TTP)</measure>
    <time_frame>From randomization up to cut-off date of 03 August 2005; up to 24 months</time_frame>
    <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)</measure>
    <time_frame>From randomization up to cut-off date of 02 March 2008; up to 51 months</time_frame>
    <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Overall Survival (OS)</measure>
    <time_frame>Randomization to data cut off of 03 August 2005; up to 24 months</time_frame>
    <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)</measure>
    <time_frame>Randomization to data cut off of 02 March 2008; up to 51 months</time_frame>
    <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Myeloma Response Rates Based on Best Response Assessment</measure>
    <time_frame>Randomization to 03 August 2005; up to 24 months</time_frame>
    <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)</measure>
    <time_frame>Randomization to data cut-off of 02 Mar 2008; up to 51 months</time_frame>
    <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months</time_frame>
    <description>An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.
The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)</measure>
    <time_frame>Up to unblinding data cut off of 03 August 2005; up to 24 months</time_frame>
    <description>Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale</measure>
    <time_frame>Randomization to cut off date of 03 August 2005; up to 24 months</time_frame>
    <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)</measure>
    <time_frame>Randomization to cut off date of 02 March 2008; up to 51 months</time_frame>
    <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>CC-5013 plus dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-5013 plus dexamethasone</intervention_name>
    <description>25 mg daily for 21 days every 28 days.</description>
    <arm_group_label>CC-5013 plus dexamethasone</arm_group_label>
    <other_name>Revlimid</other_name>
    <other_name>lenalidomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone plus Placebo</intervention_name>
    <description>Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.</description>
    <arm_group_label>Dexamethasone plus placebo</arm_group_label>
    <other_name>Dexamethasone</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.

          -  Measurable levels of myeloma paraprotein in serum or urine (24-hour collection
             sample).

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2

          -  Females of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days of starting study drug

        Exclusion Criteria:

          -  Prior development of disease progression during high-dose dexamethasone containing
             therapy

          -  Pregnant or lactating females

          -  The development of a desquamating rash while taking thalidomide

          -  Use of any standard/experimental anti-myeloma therapy within 28 days of randomization
             or use of any experimental non-drug therapy within 56 days of initiation of drug
             treatment

          -  Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm3

          -  Laboratory abnormalities: Platelet count &lt; 75,000/mm3

          -  Laboratory abnormalities: Serum creatinine &gt; 2.5 mg/dL

          -  Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase
             (SGOT)/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase
             (SGPT)/Alanine aminotransferase (ALT) &gt; 3.0 x upper limit of normal

          -  Laboratory abnormalities: Serum total bilirubin &gt; 2.0 mg/dL

          -  Prior history of malignancies other than multiple myeloma unless the subject has been
             free of the disease for ≥ 3 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Knight, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre Divsion of Haematology/Medical Oncology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <zip>VIC 3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital Oncology Research</name>
      <address>
        <city>Frankston</city>
        <zip>VIC 3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Hospital</name>
      <address>
        <city>Herston</city>
        <zip>QLD4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Public Hospital</name>
      <address>
        <city>South Brisbane</city>
        <zip>QLD 4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Salzburg St Johanns Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>A -5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Chemin Grand Revoyet</city>
        <zip>69495 Pierre Benite cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Loius</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux Groupe Hospitalier Sud</name>
      <address>
        <city>Pessac</city>
        <zip>33640</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>TSA 40031-31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hopital Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Charite</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik ChariteMedizinische Fakultaet der HumboldtUniversitaet zu Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Dusseldorf Klinik fuer Haematologie</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klininkum der Johann-Wolfgang-Goethe-Universtat</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg Medizinische Klinik und Poliklinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Muenster Medizinische Klinik A</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Univeristact Muenchen</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Alexandras&quot; General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11538</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital GalwayHaematology Department</name>
      <address>
        <city>Galway</city>
        <state>Co. Galway</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City HospitalHaematology Department</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Directorate Haematology Oncology Service St. James Hospital</name>
      <address>
        <city>Dublin 8</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidWestern Regional Hospital</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center Department of Hematology</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerita La Sapien</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista</name>
      <address>
        <city>Torio</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario a Gesttione diretta di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Internal Diseases University of Medicine</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University School of Medicine</name>
      <address>
        <city>Lublin</city>
        <zip>20-290</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Haematology and Blood Transfusion</name>
      <address>
        <city>Warsaw</city>
        <zip>00-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princessa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universtario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital Department of Hematology and Coagulation</name>
      <address>
        <city>Goteborg</city>
        <zip>S-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherkassy Regional Oncology Center</name>
      <address>
        <city>Cherkassy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnepropetrovsk City Clinical Hospital #4</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiev Bone Marrow Transplantation Center Bone Marrow Department</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Transfusiology of the UAMS Department of blood diseases</name>
      <address>
        <city>Kiev</city>
        <zip>04060</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine of the UAMS</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Blood Pathology and Transfusion Medicine of the UAMS Hematology Department</name>
      <address>
        <city>Lvov</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odess Regional Clinical Hospital</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhitomir Regional Clinical Hospital</name>
      <address>
        <city>Zhitomir</city>
        <zip>10003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital Trust</name>
      <address>
        <city>London</city>
        <state>Bloomsbury</state>
        <zip>WC1E 6AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology Dept, 4th Floor Thomas Guy House</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/clinical-study-report-csr-synopses/purposes-of-posting-clinical-study-report-csr-synopses</url>
    <description>Link to CSR synopsis</description>
  </link>
  <results_reference>
    <citation>Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007 Nov 22;357(21):2123-32. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.</citation>
    <PMID>18032762</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>February 13, 2015</results_first_submitted>
  <results_first_submitted_qc>March 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2015</results_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Celgene</keyword>
  <keyword>Revlimid</keyword>
  <keyword>CC-5013</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 55 sites in Australia, Europe, and Israel. Eligible participants were randomized in a 1:1 ratio to: lenalidomide plus oral pulse high-dose dexamethasone or Placebo plus oral pulse high-dose dexamethasone.</recruitment_details>
      <pre_assignment_details>A pre-specified interim analysis revealed a highly significant benefit favoring the lenalidomide/dexamethasone regimen, crossing the pre-specified O'Brien-Fleming superiority boundary. A decision was made to unblind the study allowing those receiving Placebo/dexamethasone to receive the lenalidomide/dexamethasone regimen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide Plus Dexamethasone (Len/Dex)</title>
          <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus Dexamethasone</title>
          <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.
Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Blinded Treatment (Up to 03 Aug 2005)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="176">Includes those who took at least one dose of study medication regimen</participants>
                <participants group_id="P2" count="175">Includes those who took at least one dose of study medication regimen</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Evaluable Population</title>
              <participants_list>
                <participants group_id="P1" count="175">1 participant excluded because they had no baseline M-protein assessment</participants>
                <participants group_id="P2" count="171">4 participants excluded because they had no baseline M-protein assessment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54">54 participants ongoing and continuing on lenalidomide/dexamethasone treatment</participants>
                <participants group_id="P2" count="19">Ongoing and includes 15 participants who crossed over to lenalidomide/dexamethasone after unblinding</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>On Study at Time of Unblinding</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176">Refers to original treatment group assignment in the study.</participants>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21">Participants completed = those continuing on long term Lenalidomide and dexamethasone</participants>
                <participants group_id="P2" count="8">Participants completed = those continuing on long term dexamethasone</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="167"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of disease</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long Term Extension (Up to 25 Jun 2013)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="8">2 participants opted to receive dex alone, 3 crossed over to Len/Dex and 3 added Len at a later date</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of Disease</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat population included all participants who were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide Plus Dexamethasone</title>
          <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus Dexamethasone</title>
          <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="175"/>
            <count group_id="B3" value="351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="10.12"/>
                    <measurement group_id="B2" value="62.9" spread="8.80"/>
                    <measurement group_id="B3" value="62.6" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status is used by doctors and researchers to assess how a participants' disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0 = (Fully Active)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 = (Restrictive but Ambulatory)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 = Ambulatory unable to Work)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 = (Limited Self-Care)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 = (Completely Disabled)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior Anti-Myeloma Therapies</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 Prior anti-myeloma therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 or more prior anti-myeloma therapies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from First Pathological Diagnosis</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" lower_limit="0.4" upper_limit="15.7"/>
                    <measurement group_id="B2" value="4.0" lower_limit="0.3" upper_limit="26.6"/>
                    <measurement group_id="B3" value="3.7" lower_limit="0.3" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline multiple myeloma stage</title>
          <description>The International Staging System divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels.
Stage I: Serum beta-2 microglobulin is less than 3.5 (mg/L) and the albumin level is above 3.5 (g/L);
Stage II: Neither stage I or III, meaning that either:
The beta-2 microglobulin level is between 3.5 and 5.5 (with any albumin level), OR
The albumin is below 3.5 while the beta-2 microglobulin is less than 3.5
Stage III: Serum beta-2 microglobulin is greater than 5.5.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of Time to Tumor Progression (TTP)</title>
        <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>From randomization up to cut-off date of 03 August 2005; up to 24 months</time_frame>
        <population>Intent to treat included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Time to Tumor Progression (TTP)</title>
          <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Intent to treat included all participants who were randomized.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="40.9">Unable to provide as data not yet estimable</measurement>
                    <measurement group_id="O2" value="20.1" lower_limit="16.6" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.324</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.240</ci_lower_limit>
            <ci_upper_limit>0.438</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (Lenalidomide/Dex:Placebo/Dexamethasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Overall Survival (OS)</title>
        <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
        <time_frame>Randomization to data cut off of 03 August 2005; up to 24 months</time_frame>
        <population>Intent to Treat population includes all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Overall Survival (OS)</title>
          <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
          <population>Intent to Treat population includes all participants who were randomized.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA: Data not considered materialized or estimable at this time point</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="71.6">NA: Data not considered materialized or estimable at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.105</p_value>
            <method>Log Rank</method>
            <method_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.730</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.498</ci_lower_limit>
            <ci_upper_limit>1.070</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (Lenalidomide/Dexamethasone:Placebo/Dexamethasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)</title>
        <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
        <time_frame>Randomization to data cut off of 02 March 2008; up to 51 months</time_frame>
        <population>Intent to Treat population includes all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days.
Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)</title>
          <description>OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.</description>
          <population>Intent to Treat population includes all participants who were randomized.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.9" lower_limit="129.3" upper_limit="201.4"/>
                    <measurement group_id="O2" value="133.3" lower_limit="101.6" upper_limit="174.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.302</p_value>
            <method>Log Rank</method>
            <method_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.863</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.651</ci_lower_limit>
            <ci_upper_limit>1.143</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Myeloma Response Rates Based on Best Response Assessment</title>
        <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
        <time_frame>Randomization to 03 August 2005; up to 24 months</time_frame>
        <population>Intent to Treat Population includes all participants who were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Myeloma Response Rates Based on Best Response Assessment</title>
          <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
          <population>Intent to Treat Population includes all participants who were randomized</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable (NE) those without response data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Probability from Wilcoxon rank sum test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)</title>
        <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
        <time_frame>Randomization to data cut-off of 02 Mar 2008; up to 51 months</time_frame>
        <population>Intent to Treat Population includes all participants who were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days.
Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)</title>
          <description>Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma.</description>
          <population>Intent to Treat Population includes all participants who were randomized</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0"/>
                    <measurement group_id="O2" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="56.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable (NE) those without response data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Probability from Wilcoxon rank sum test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE)</title>
        <description>An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.
The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.</description>
        <time_frame>From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months</time_frame>
        <population>The safety population includes all participants who received at least one dose of study drug regimen</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days. Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE)</title>
          <description>An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.
The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death.</description>
          <population>The safety population includes all participants who received at least one dose of study drug regimen</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 1 Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 AE leading to dose reduction or interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Drug-Related Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Drug-Related Serious Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥Death within ≤ 30 days of last dose of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 1 or Higher Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 2 or Higher Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 3 or Higher Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 1 Grade 4 or Higher Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)</title>
        <description>Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).</description>
        <time_frame>Up to unblinding data cut off of 03 August 2005; up to 24 months</time_frame>
        <population>Analysis not performed due to an insufficient number of participants with SRE</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)</title>
          <description>Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone).</description>
          <population>Analysis not performed due to an insufficient number of participants with SRE</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">There were an insufficient number of participants with SRE events and no analysis was conducted.</measurement>
                    <measurement group_id="O2" value="NA">There were an insufficient number of participants with SRE events and no analysis was conducted.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of Duration of Response</title>
        <description>Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.</description>
        <time_frame>Up to data cut off of 03 August 2005; up to 24 months</time_frame>
        <population>Intent to Treat population includes all participants who were randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Duration of Response</title>
          <description>Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.</description>
          <population>Intent to Treat population includes all participants who were randomized to study drug.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" lower_limit="42.1">NA: Data not considered materialized or estimable at this time point</measurement>
                    <measurement group_id="O2" value="33.3" lower_limit="22.1" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>Log Rank</method>
            <method_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.558</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.338</ci_lower_limit>
            <ci_upper_limit>0.921</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (lenalidomide/dexamethasone : placebo/dexamethasone).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)</title>
        <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
        <time_frame>From randomization up to cut-off date of 02 March 2008; up to 51 months</time_frame>
        <population>Intent to treat included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Pulse dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days.
Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned. After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)</title>
          <description>Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.</description>
          <population>Intent to treat included all participants who were randomized.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="40.9" upper_limit="85.6"/>
                    <measurement group_id="O2" value="20.1" lower_limit="16.6" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.362</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.478</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale</title>
        <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
        <time_frame>Randomization to cut off date of 03 August 2005; up to 24 months</time_frame>
        <population>Intent to Treat includes all participants who were randomized to study drug; a total of six ECOG scores were missing at the time of the Aug 2005 cut-off.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale</title>
          <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
          <population>Intent to Treat includes all participants who were randomized to study drug; a total of six ECOG scores were missing at the time of the Aug 2005 cut-off.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.1" upper_limit="16.1"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.1" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.271</p_value>
            <p_value_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.887</ci_lower_limit>
            <ci_upper_limit>1.532</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (lenalidomide/dexamethasone: placebo/dexamethasone)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)</title>
        <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
        <time_frame>Randomization to cut off date of 02 March 2008; up to 51 months</time_frame>
        <population>Intent to Treat includes all participants who were randomized to study drug; six ECOG scores were missing at the March 2008 cut-off.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days. Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)</title>
          <description>The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented.</description>
          <population>Intent to Treat includes all participants who were randomized to study drug; six ECOG scores were missing at the March 2008 cut-off.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.1" upper_limit="16.1"/>
                    <measurement group_id="O2" value="12.3" lower_limit="10.1" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.359</p_value>
            <p_value_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.135</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.866</ci_lower_limit>
            <ci_upper_limit>1.486</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Kaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008)</title>
        <description>Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.</description>
        <time_frame>Up to data cut off of 03 Mar 2008; up to 51 months</time_frame>
        <population>Intent to Treat population includes all participants who were randomized to study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide Plus Dexamethasone</title>
            <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus Dexamethasone</title>
            <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle. Pulse dexamethasone 40 mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40 mg PO QD for Days 1-4 every 28 days. Participants with documented progressive disease were permitted to crossover to receive lenalidomide at the same doses mentioned.
After the study was unblinded in August 2005 participants were given the option to add lenalidomide to their dexamethasone treatment regimen immediately or to add lenalidomide to their dexamethasone therapy at the time of disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of Duration of Response (Cut-off at a Later Date of 03 March 2008)</title>
          <description>Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression.</description>
          <population>Intent to Treat population includes all participants who were randomized to study drug.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="42.1" upper_limit="105.6"/>
                    <measurement group_id="O2" value="33.3" lower_limit="22.1" upper_limit="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Log Rank</method>
            <method_desc>The p-value is based on an unstratified log rank test of survival curve differences between the treatment groups.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.619</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.398</ci_lower_limit>
            <ci_upper_limit>0.964</ci_upper_limit>
            <estimate_desc>Based on a proportional hazards model comparing the hazard functions associated with the treatment groups (CC-5013/Dex:Placebo/Dex)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to 30 days after the last visit. Up to 25 Jun 2013 (90 Months).</time_frame>
      <desc>Includes adverse events for those who received Lenalidomide after unblinding.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide Plus Dexamethasone</title>
          <description>Lenalidomide 25 mg by mouth (PO) daily (QD) on Days 1 to 21 and a matching placebo capsule QD on Days 22 to 28 of each 28-day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28 day cycle for cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD on Days 1 to 4 every 28 days for the remaining cycles.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus Dexamethasone</title>
          <description>Placebo PO daily on Days 1 to 28 of each 28 day cycle.
Dexamethasone 40mg PO QD on Days 1-4, 9-12, and 17-20 of each 28-day cycle for Cycles 1 through 4. Beginning with Cycle 5, dexamethasone dosing schedule was reduced to 40mg PO QD for Days 1-4 every 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERVISCOSITY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THROMBOTIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY OEDEMA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VENTRICULAR BIGEMINY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ACQUIRED HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ADRENAL INSUFFICIENCY NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CORNEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EXOPHTHALMOS NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CAECITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COLOVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTRITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VOMITING NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIFFICULTY IN WALKING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERFORMANCE STATUS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GRANULOMA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NECROSIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 15.1">PNEUMONIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.1">RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.1">SEPSIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHITIS ACUTE NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS CARINII PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BURSITIS INFECTIVE NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CENTRAL LINE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MENINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MENINGITIS PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NECROTISING FASCIITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA LEGIONELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SALMONELLA INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUSITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 15.1">URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THORACIC VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCAEMIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN IN LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST WALL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYOPATHY STEROID</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OSTEOPOROSIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN IN JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SPONDYLITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BREAST CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NEOPLASM NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA, STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EPIDURITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL PRESSURE INCREASED NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LEUKOENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NEUROPATHY NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MANIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FANCONI SYNDROME ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE ON CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST MICROCALCIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LUNG CONSOLIDATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MAXILLARY SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPLAKIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOTENSION NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PHLEBITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS NOS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PHLEBOTHROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="175" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>CUSHINGOID</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIARRHOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>VOMITING NOS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN NO</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTRITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>OEDEMA NOS</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SINUSITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE CRAMP</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MUSCLE WEAKNESS NOS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PAIN IN LIMB</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CHEST WALL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DYSPNOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>BRONCHITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>RHINITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH NOS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>SWEATING INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="175"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION NOS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator has the right to publish and/or present study data after multicentric publication or one year has elapsed until completion of this multicentric study provided that he/she (i) furnishes the sponsor a copy of any proposed publication or presentation before its submission, (ii) deletes any sponsor’s confidential data as pointed out by sponsor, and (iii) delays any submission for generally up to ninety (90) days to permit the preparation and filing of intellectual property applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne McClain, Senior Manager</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>1-866-260-1599</phone>
      <email>ClinicalTrialDisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

